Clinical practice experience with testosterone treatment in men with testosterone deficiency syndrome

BJU International

Volumn 102, Issue 9, 2008, Pages 1142-1146

  McLaren, Drew ^a   Siemens, D Robert ^a,b   Izard, Jason ^a   Black, Angela ^a   Morales, Alvaro ^a  

^a QUEEN S UNIVERSITY   (Canada)

^b KINGSTON GENERAL HOSPITAL   (Canada)

Author keywords

PSA; Testosterone; Testosterone deficiency syndrome

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE; TESTOSTERONE ESTER; TESTOSTERONE UNDECANOATE;

ADULT; AGED; ARTICLE; CLINICAL PRACTICE; CONTROLLED STUDY; DRUG WITHDRAWAL; FOLLOW UP; HORMONE DEFICIENCY; HORMONE SUBSTITUTION; HUMAN; LIBIDO; LOWER URINARY TRACT SYMPTOM; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; PENIS ERECTION; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; SEXUAL FUNCTION; TESTOSTERONE DEFICIENCY SYNDROME; UNSPECIFIED SIDE EFFECT;

AGED; AGING; COHORT STUDIES; HORMONE REPLACEMENT THERAPY; HUMANS; LIBIDO; MALE; MIDDLE AGED; PENILE ERECTION; PROSTATE-SPECIFIC ANTIGEN; QUALITY OF LIFE; RETROSPECTIVE STUDIES; SYNDROME; TESTOSTERONE; TREATMENT OUTCOME;

EID: 53849093066     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2008.07811.x     Document Type: Article

References (25)

1. Tariq SH, Haren MT, Kim MJ, Morley JE. Andropause: is the emperor wearing any clothes? Rev Endocr Metab Disord 2005 6 : 77 84
2. Handelsman DJ, Liu PY. Andropause: invention, prevention, rejuvenation. Trends Endocrinol Metab 2005 16 : 39 45
3. Hijazi RA, Cunningham GR. Andropause: is androgen replacement therapy indicated for the aging male? Annu Rev Med 2005 56 : 117 37
4. Araujo AB, O'Donnell AB, Brambilla DJ et al. Prevalence and incidence of androgen deficiency in middle-aged and older men: estimates from the Massachusetts Male Aging Study. J Clin Endocrinol Metab 2004 89 : 5920 6
5. Araujo AB, Esche GR, Kupelian V et al. Prevalence of symptomatic androgen deficiency in men. J Clin Endocrinol Metab 2007 92 : 4241 7
6. Liverman CT, Blazer DG eds. Testosterone and Aging, Clinical Research Directions. Washington, DC : Institute of Medicine of The National Academies, 2004
7. McLachlan RI, Allan CA. Defining the prevalence and incidence of androgen deficiency in aging men: where are the goal posts? J Clin Endocrinol Metab 2004 89 : 5916 9
8. Cunningham G, Swerdloff RS. Summary from the Second Annual Andropause Consensus Meeting 2001. Available at: http://endo-society.net/publicpolicy/ legislative/upload/andro_cc_summary.pdf. Accessed April 2008
9. Haren M, Chapman I, Coates P, Morley J, Wittert G. Effect of 12 month oral testosterone on testosterone deficiency symptoms in symptomatic elderly males with low-normal gonadal status. Age Ageing 2005 34 : 125 30
10. Arver S, Dobs AS, Meikle AW, Allen RP, Sanders SW, Mazer NA. Improvement of sexual function in testosterone deficient men treated for 1 year with a permeation enhanced testosterone transdermal system. J Urol 1996 155 : 1604 8
11. Schultheiss D, Machtens S, Jonas U. Testosterone therapy in the ageing male: what about the prostate? Andrologia 2004 36 : 355 65
12. Monath JR, McCullough DL, Hart LJ, Jarow JP. Physiologic variations of serum testosterone within the normal range do not affect serum prostate-specific antigen. Urology 1995 46 : 58 61
13. El-Sakka AI, Hassoba HM, Elbakry AM, Hassan HA. Prostatic specific antigen in patients with hypogonadism: effect of testosterone replacement. J Sex Med 2005 2 : 235 40
14. Marks LS, Mazer NA, Mostaghel E et al. Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: a randomized controlled trial. JAMA 2006 296 : 2351 61
15. Calof OM, Singh AB, Lee ML et al. Adverse events associated with testosterone replacement in middle- aged and older men: a meta-analysis of randomized, placebo-controlled trials. J Gerontol A Biol Sci Med 2005 60 : 1451 7
16. Swerdloff RS, Wang C. Three-year follow-up of androgen treatment in hypogonadal men: preliminary report with testosterone gel. Aging Male 2003 6 : 207 11
17. Amory JK, Watts NB, Easley KA et al. Exogenous testosterone or testosterone with finasteride increases bone mineral density in older men with low serum testosterone. J Clin Endocrinol Metab 2004 89 : 503 10
18. Bhasin S, Singh AB, Mac RP, Carter B, Lee MI, Cunningham GR. Managing the risks of prostate disease during testosterone replacement therapy in older men: recommendations for a standardized monitoring plan. J Androl 2003 24 : 299 311
19. Morales A. Monitoring androgen replacement therapy: testosterone and prostate safety. J Endocrinol Invest 2005 28 (Suppl. 122 7
20. Tan RS, Culberson JW. An integrative review on current evidence of testosterone replacement therapy for the andropause. Maturitas 2003 45 : 15 27
21. Collier CP, Clark AF, Bain J et al. Functional testosterone: biochemical assessment of hypogonadism in men - report from a multidisciplinary workshop hosted by the Ontario Society of Clinical Chemists. Aging Male 2007 10 : 211 6
22. Emadi-Konjin P, Bain J, Bromberg IL. Evaluation of an algorithm for calculation of serum 'bioavailable' testosterone (BAT). Clin Biochem 2003 36 : 591 6
23. Black AM, Day AG, Morales A. The reliability of clinical and biochemical assessment in symptomatic late-onset hypogonadism: can a case be made for a 3-month therapeutic trial? BJU Int 2004 94 : 1066 70
24. Mooradian AD, Korenman SG. Management of the cardinal features of andropause. Am J Ther 2006 13 : 145 60
25. Lapauw B, Goemaere S, Crabbe P, Kaufman JM, Ruige JB. Is the effect of testosterone on body composition modulated by the androgen receptor gene CAG repeat polymorphism in elderly men? Eur J Endocrinol 2007 156 : 395 401